Oral Abstract

83 - Late Breaker Oral Abstract Session 1

Presentations:

• 1:45 PM - 1:55 PM

  LB1 - Regional assessment and containment of Candida auris transmission in post-acute care settings — Orange County, California, 2019
  Ellora Karmarkar, MD;MSC – Centers for Disease Control and Prevention; Kathleen O'Donnell, MPH – Orange County Health Care Agency; Christopher Prestel, MD – Centers for Disease Control and Prevention; Kaitlin Forsberg, MPH – Centers for Disease Control and Prevention; IHRC, Inc.; Douglas K. Schan, PHM, MPH – Orange County Health Care Agency; Nancy A. Chow, PhD – CDC; Darby S. McDermott, DVM, MPH – Mycotic Diseases Branch; John A. Rossow, DVM, MPH – Centers for Disease Control and Prevention; Mitsuru Toda, PhD – Centers for Disease Control and Prevention; Janet Glowicz, PhD – Centers for Disease Control and Prevention; Richard Brooks, MD, MPH – Centers for Disease Control and Prevention; Hosniyeh Bagheri, n/a – California Department of Public Health (CDPH); Teresa Nelson, RN BS CIC – California Department of Public Health; Nicole Gualandi, MS/MPH, RN, CIC, FAPIC – CDC; Zenith Khwaja, RN, MSN, MPH, CIC – CDPH; Sam Horwich-Scholefield, MPH CIC – California Department of Public Health; Joshua Jacobs, MA – Orange County Health Care Agency; Michele Cheung, MD, MPH – Orange County Health Care Agency; Lydia Mikhail, PHM, MBA – Orange County Health Care Agency; Maroya S. Walters, PhD, ScM – Centers for Disease Control and Prevention; Kara Jacobs-Slifka, MD, MPH – CDC Division of Healthcare Quality and Promotion; Nimalie D. Stone, MD, MS – CDC Division of Healthcare Quality and Promotion; Lalitha Gade, Masters in Pharmaceutical Sciences – CDC; Elizabeth L. Berkow, Ph.D. – Centers for Disease Control and Prevention; Brendan R. Jackson, MD, MPH – Centers for Disease Control and Prevention; Snigdha Vallabhaneni, MD, MPH – CDC; Matt Zahn, MD – Orange County Health Care Agency; Erin Epson, MD – California Department of Public Health
• 1:55 PM - 2:05 PM

  LB2 - TORC1 Inhibition with RTB101 as a Potential Pan-Antiviral Immunotherapy to Decrease the Incidence of Respiratory Tract Infections Due to Multiple Respiratory Viruses in Older Adults
  Joan Mannick, MD – resTORbio, Inc; Amelia Tomlinson, PHD – resTORbio, Inc; Sarb Shergill, PhD – resTORbio, Inc; Grace Teo, PhD – resTORbio; Lloyd Klickstein, MD, PhD – resTORbio
• 2:05 PM - 2:15 PM

  LB3 - Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study
  Cara Cassino, MD – ContraFect Corporation; Hemal Shah, PharmD – Value Matters; Joy Lipka-Diamond, MS – Lipka Consulting; Anita F. Das, PhD – AD Stat Consulting
• 2:15 PM - 2:25 PM

  LB4 - Efficacy and Safety of Cefiderocol versus High-Dose Meropenem in Patients with Nosocomial Pneumonia – Results of a Phase 3 Randomized, Multicenter, Double-Blind, Non-Inferiority Study
  Richard G. Wunderink, MD – Northwestern University Feinberg School of Medicine; Yuko Matsunaga, MD – Shionogi Inc.; Mari Ariyasu, BPharm – Shionogi & Co., Ltd.; Roger Echols, MD – Infectious Disease Drug Development Consulting LLC; Anju Menon, PhD – Shionogi Inc.; Tsutae Den Nagata, MD – Shionogi & Co., Ltd.
• 2:25 PM - 2:35 PM

  LB5 - A Long Time Coming: Final Two-Year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
  Robert Orenstein, DO – Mayo Clinic in Arizona; Sarah Mische, PhD – Rebiotix Inc.; Ken Blount, PhD – Rebiotix Inc.; Lindy Bancke, PharmD – Rebiotix Inc.; Xin Su, MD, MSci – Rebiotix Inc; Dana Walsh, PhD – Rebiotix Inc.; Adam Harvey, PhD – Rebiotix Inc; Carlos Gonzalez, MS – BioRankings, LLC; Dale N. Gerding, MD – Edward Hines Jr. VA Hospital
• 2:35 PM - 2:45 PM

  LB6 - EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
  Eoin Coakley, MD – Enanta Pharmaceuticals; Alaa Ahmad, PhD – Enanta Pharmaceuticals; Kajal Larson, PhD – Enanta Pharmaceuticals; Ty McClure, PhD – Enanta Pharmaceuticals; Kai Lin, PhD – Enanta Pharmaceuticals; Kursten Tenhoor, n/a – Enanta Pharmaceuticals; Kingsley Eze, n/a – hVIVO Services Ltd; Nicolas Noulin, PhD – hVivo Services LTD; Veronika Horvathova, MBChB, MSc – hVivo Services LTD; Bryan Murray, MBBS – BJM Pharma Consulting Ltd; Mark Baillet, PhD – S-cubed Biometrics Limited; Julie Mori, PhD – hVivo Services LTD; Nathalie Adda, MD – Enanta Pharmaceuticals
• 2:45 PM - 2:55 PM

  LB7 - A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor
  Kevin W. Garey, MS;PharmD – University of Houston College of Pharmacy; Martin Kankam, MD, PhD, MPH – Altasciences; Julie Mercier, BS – Altasciences; Corinne Seng Yue, BPharm, MSc, PhD – Learn and Confirm, Inc; Murray Ducharme, PharmD – Learn and Confirm, Inc; Anne J. Gonzales-Luna, PharmD – University of Houston; M Jahangir Alam, PhD – University of Houston College of Pharmacy; Khurshida Begum, PhD – University of Houston College of Pharmacy; Michael Silverman, MD – Acurx Pharmaceuticals, LLC

Co-Author(s)

• RO

  Robert Orenstein, DO

  Infectious Disease Specialist
  Mayo Clinic in Arizona
  Phoenix, AZ

  Disclosure: Rebiotix Inc.: Advisor or Review Panel member
• RW

  Richard Wunderink, MD

  Dr.
  Northwestern University Feinberg School of Medicine
  Chicago, IL

  Disclosure: Merck: Consultant, Grant/Research Support
  Shionogi Inc.: Consultant
• AA

  Alaa Ahmad, PhD

  Senior Director & Head, Clinical Pharmacology
  Enanta Pharmaceuticals
  Watertown, MA

  Disclosure: Enanta Pharmaceuticals: Employee
• MK

  Martin Kankam, MD, PhD, MPH

  Principal Investigator
  Altasciences
  Kansas City, KS

  Disclosure: Acurx Pharmaceuticals, LLC: Research Grant or Support
• SM

  Sarah Mische, PhD

  Assoc. Director of Clinical Research
  Rebiotix Inc.
  Roseville, MN

  Disclosure: Rebiotix Inc.: Employee
• KO

  Kathleen O'Donnell, MPH

  Epidemiologist
  Orange County Health Care Agency
  Los Angeles, CA

  Disclosure: Nothing to disclose
• HS

  Hemal Shah, PharmD

  principal/consultant
  Value Matters
  Ridgefield, CT

  Disclosure: Boehringer Ingelheim: Consultant
  ContraFect Corp: Consultant
  DBV Technologies: Consultant
  Mylan specialty: Consultant
  Nabriva: Consultant
• AT

  Amelia Tomlinson, PHD

  Director of Clinical Sciences
  resTORbio, Inc
  Boston, MA

  Disclosure: resTORbio: Employee
• MA

  Mari Ariyasu, BPharm

  Senior Director
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd.: Employee
• KL

  Kajal Larson, PhD

  Clinical Pharmacology Lead
  Enanta Pharmaceuticals
  Watertown, MA

  Disclosure: Enanta Pharmaceuticals: Employee
• JL

  Joy Lipka-Diamond, MS

  Consultant
  Lipka Consulting
  Mullica Hill, NJ

  Disclosure: ContraFect Corporation: Consultant
• JM

  Julie Mercier, BS

  Team Manager (BPI)
  Altasciences
  Montreal, QC, Canada

  Disclosure: Acurx Pharmaceuticals, LLC: Research Grant or Support
• CP

  Christopher Prestel, MD

  Epidemic Intelligence Service Officer
  Centers for Disease Control and Prevention
  Decatur, GA

  Disclosure: Nothing to disclose
• SS

  Sarb Shergill, PhD

  Senior Vice President
  resTORbio, Inc
  Boston, MA

  Disclosure: resTORbio: Employee
• LB

  Lindy Bancke, PharmD

  Head of Clinical Development
  Rebiotix Inc.
  Roseville, MN

  Disclosure: Rebiotix Inc.: Employee
• AD

  Anita Das, PhD

  Project Statistician
  AD Stat Consulting
  Guerneville, CA

  Disclosure: Achaogen: Consultant
  AntiobioTx: Consultant
  Boston Pharmaceuticals: Consultant
  Cempra: Consultant
  ContraFect Corporation: Consultant
  Iterum Therapeutics: Consultant
  Nabriva: Consultant
  Paratek: Consultant
  Tetraphase: Consultant
  UTILITY: Consultant
  Wockhardt: Consultant
• RE

  Roger Echols, MD

  Consultant
  Infectious Disease Drug Development Consulting LLC
  Easton, Connecticut

  Disclosure: Shionogi Inc.: Consultant
• KF

  Kaitlin Forsberg, MPH

  Epidemiologist
  Centers for Disease Control and Prevention; IHRC, Inc.
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• TM

  Ty McClure, PhD

  Executive Director & Head, Biometrics
  Enanta Pharmaceuticals
  Watertown, MA

  Disclosure: Enanta Pharmaceuticals: Employee
• GT

  Grace Teo, PhD

  Senior Director, Research
  resTORbio
  Boston, MA

  Disclosure: resTORbio: Employee
• CY

  Corinne Seng Yue, BPharm, MSc, PhD

  Vice-President Clinical Pharmacology and Pharmacometrics
  Learn and Confirm, Inc
  Montreal, QC, Canada

  Disclosure: Acurx Pharmaceuticals, LLC: Grant/Research Support
• MD

  Murray Ducharme, PharmD

  President and CEO
  Learn and Confirm, Inc
  Montreal, QC, Canada

  Disclosure: Acurx Pharmaceuticals, LLC: Grant/Research Support
• LK

  Lloyd Klickstein, MD, PhD

  Chief Scientific Officer
  resTORbio
  Boston, MA

  Disclosure: resTORbio: Employee
• KL

  Kai Lin, PhD

  Senior Director
  Enanta Pharmaceuticals
  Watertown, MA

  Disclosure: Enanta Pharmaceuticals: Employee
• AM

  Anju Menon, PhD

  Senior Biostatistician
  Shionogi Inc.
  Florham Park, NJ

  Disclosure: Shionogi Inc.: Employee
• DS

  Douglas Schan, PHM, MPH

  Public Health Microbiologist
  Orange County Health Care Agency
  Santa Ana, CA

  Disclosure: Nothing to disclose
• XS

  Xin Su, MD, MSci

  Principal Clinical Research Scientist
  Rebiotix Inc
  Roseville, MN

  Disclosure: Rebiotix Inc.: Employee
• NC

  Nancy Chow, PhD

  Molecular epidemiologist
  CDC
  Atlanta, GA

  Disclosure: Nothing to disclose
• AG

  Anne Gonzales-Luna, PharmD

  Post-Doctoral Fellow
  University of Houston
  Houston, TX

  Disclosure: Nothing to disclose
• TN

  Tsutae Den Nagata, MD

  Senior Vice President
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd.: Employee
• KT

  Kursten Tenhoor, n/a

  Consultant
  Enanta Pharmaceuticals
  Watertown, MA

  Disclosure: Enanta Pharmaceuticals: Consultant
• DW

  Dana Walsh, PhD

  Scientist
  Rebiotix Inc.
  Roseville, MN

  Disclosure: Rebiotix Inc.: Employee
• MA

  M Jahangir Alam, PhD

  Assistant Professor
  University of Houston College of Pharmacy
  Houston, TX

  Disclosure: Nothing to disclose
• KE

  Kingsley Eze, n/a

  Project Director
  hVIVO Services Ltd
  London, England, United Kingdom

  Disclosure: hVIVO Services Ltd: Employee
• AH

  Adam Harvey, PhD

  Senior Clinical Research Scientist
  Rebiotix Inc
  Roseville, MN

  Disclosure: Rebiotix Inc.: Employee
• DM

  Darby McDermott, DVM, MPH

  Epidemiology Elective Fellow
  Mycotic Diseases Branch
  Philadelphia, PA

  Disclosure: Nothing to disclose
• KB

  Khurshida Begum, PhD

  Research scientist
  University of Houston College of Pharmacy
  Houston, TX

  Disclosure: Nothing to disclose
• CG

  Carlos Gonzalez, MS

  Statistician
  BioRankings, LLC
  St. Louis, Missouri

  Disclosure: Rebiotix Inc.: Consultant
• NN

  Nicolas Noulin, PhD

  Associate Director, Clinical Science
  hVivo Services LTD
  London, England, United Kingdom

  Disclosure: Nothing to disclose
• JR

  John Rossow, DVM, MPH

  Epidemic Intelligence Service Officer
  Centers for Disease Control and Prevention
  Atlanta, GA

  Disclosure: Nothing to disclose
• DG

  Dale Gerding, MD

  Research Physician
  Edward Hines Jr. VA Hospital
  Hines, IL

  Disclosure: Rebiotix Inc.: Board Member
• VH

  Veronika Horvathova, MBChB, MSc

  Associate Medical Director
  hVivo Services LTD
  London, England, United Kingdom

  Disclosure: hVIVO Services Limited: Other Financial or Material Support, Employed by hVIVO during the conduct of the study.
• MS

  Michael Silverman, MD

  Medical Director
  Acurx Pharmaceuticals, LLC
  White Plains, NY

  Disclosure: Acurx Pharmaceuticals, LLC: Consultant, Employee, Shareholder
• MT

  Mitsuru Toda, PhD

  Epidemiologist
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• JG

  Janet Glowicz, PhD

  Nurse Consultant
  Centers for Disease Control and Prevention
  Denton, Texas

  Disclosure: Nothing to disclose
• BM

  Bryan Murray, MBBS

  Medical Monitor
  BJM Pharma Consulting Ltd
  London, England, United Kingdom

  Disclosure: Nothing to disclose
• MB

  Mark Baillet, PhD

  Managing Director and Consultant Statistician
  S-cubed Biometrics Limited
  London, England, United Kingdom

  Disclosure: S-CUBED: Employee
• RB

  Richard Brooks, MD, MPH

  Field Medical Officer
  Centers for Disease Control and Prevention
  Baltimore, MD

  Disclosure: Nothing to disclose
• HB

  Hosniyeh Bagheri, n/a

  Liaison Infection Preventionist
  California Department of Public Health (CDPH)
  Rancho Santa Margarita, CA

  Disclosure: Nothing to disclose
• JM

  Julie Mori, PhD

  Principal Virologist
  hVivo Services LTD
  London, England, United Kingdom

  Disclosure: hVIVO: Employee, Shareholder
• NA

  Nathalie Adda, MD

  Senior Vice President & Chief Medical Officer
  Enanta Pharmaceuticals
  Watertown, MA

  Disclosure: Enanta Pharmaceuticals: Employee
• TN

  Teresa Nelson, RN BS CIC

  Teresa Nelson RN Infection Preventionist Liaison with Ca Dept. Public Health
  California Department of Public Health
  Redlands, CA

  Disclosure: Nothing to disclose
• NG

  Nicole Gualandi, MS/MPH, RN, CIC, FAPIC

  Infection Preventionist
  CDC
  Atlanta, GA

  Disclosure: Nothing to disclose
• ZK

  Zenith Khwaja, RN, MSN, MPH, CIC

  Infection Preventionist
  CDPH
  Richmond, CA

  Disclosure: Nothing to disclose
• SH

  Sam Horwich-Scholefield, MPH CIC

  Antimicrobial Resistance Epidemiologist
  California Department of Public Health
  Oakland, CA

  Disclosure: Nothing to disclose
• JJ

  Joshua Jacobs, MA

  Division Manager, Communicable Disease Control
  Orange County Health Care Agency
  Santa Ana, CA

  Disclosure: Nothing to disclose
• MC

  Michele Cheung, MD, MPH

  Deputy Medical Director, Epidemiology
  Orange County Health Care Agency
  Santa Ana, CA

  Disclosure: Nothing to disclose
• LM

  Lydia Mikhail, PHM, MBA

  Laboratory Manager
  Orange County Health Care Agency
  Orange County, CA

  Disclosure: Nothing to disclose
• MW

  Maroya Walters, PhD, ScM

  Lead, Antimicrobial Resistance Team
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• KJ

  Kara Jacobs-Slifka, MD, MPH

  Long Term Care Team Medical Officer
  CDC Division of Healthcare Quality and Promotion
  Atlanta, GA

  Disclosure: Nothing to disclose
• 

  Nimalie Stone, MD, MS

  Long Term Care Team Lead
  CDC Division of Healthcare Quality and Promotion
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• LG

  Lalitha Gade, Masters in Pharmaceutical Sciences

  Biologist
  CDC
  Lilburn, GA

  Disclosure: Nothing to disclose
• EB

  Elizabeth Berkow, Ph.D.

  Laboratory Team Lead
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• BJ

  Brendan Jackson, MD, MPH

  Medical Epidemiologist
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• 

  Snigdha Vallabhaneni, MD, MPH

  Medical epidemiologist
  CDC
  Atlanta, GA

  Disclosure: Nothing to disclose
• MZ

  Matt Zahn, MD

  Medical Director
  Orange County Health Care Agency
  Orange County, CA

  Disclosure: Nothing to disclose
• EE

  Erin Epson, MD

  Assistant Chief of Health Care Associated Infections Program
  California Department of Public Health
  Richmond, CA

  Disclosure: Nothing to disclose

Moderator(s)

• 

  Nimalie Stone, MD, MS

  Long Term Care Team Lead
  CDC Division of Healthcare Quality and Promotion
  Atlanta, Georgia

  Disclosure: Nothing to disclose
• 

  Jason Pogue, PharmD, BCPS, BCIDP

  Clinical Professor
  University of Michigan
  Ann Arbor, Michigan

  Disclosure: Accelerate Diagnostics: Consultant
  Melinta Therapeutoics: Consultant
  Merck and Co.: Consultant, Research Grant
  Nabriva Therapeutics: Consultant
  Paratek Pharmaceuticals: Consultant
  Qpex: Consultant
  Shionogi: Consultant
  Tetraphase Pharmaceuticals: Consultant

Presenting Author(s)

• CC

  Cara Cassino, MD

  Chief Medical Officer and Executive Vice President of Research and Development
  ContraFect Corporation
  Yonkers, NY

  Disclosure: ContraFect Corporation: Employee
• EC

  Eoin Coakley, MD

  Senior Director Clinical Research
  Enanta Pharmaceuticals
  Boston, MA

  Disclosure: Enanta Pharmaceuticals: Employee
• KG

  Kevin Garey, MS;PharmD

  Professor and Chair
  University of Houston College of Pharmacy
  Houston, Texas

  Disclosure: Acurx: Grant/Research Support
• EK

  Ellora Karmarkar, MD;MSC

  Epidemic Intelligence Service Officer
  Centers for Disease Control and Prevention
  Richmond, CA

  Disclosure: Nothing to disclose
• JM

  Joan Mannick, MD

  Chief Medical Officer
  resTORbio, Inc
  Boston, MA

  Disclosure: resTORbio: Employee, Shareholder
• YM

  Yuko Matsunaga, MD

  Medical Director
  Shionogi Inc.
  Florham Park, New Jersey

  Disclosure: Shionogi Inc.: Employee
• KB

  Ken Blount, PhD

  Chief Scientific Officer
  Rebiotix Inc.
  Roseville, MN

  Disclosure: Rebiotix Inc.: Employee